Veterinary Stents Market: as rising tracheal collapse prevalence in small dog breeds sustains nitinol airway stent demand and clinical evidence for human-grade silicone stents repurposed in dogs continues to accumulate, minimally invasive interventional veterinary medicine is expanding its toolkit largely by adapting proven human device platforms rather than through veterinary-specific device innovation.

The global veterinary stents market size was USD 51.8 Million in 2025 and is expected to register a revenue CAGR of 6.9% during the forecast period.Market revenue growth is driven by factors such as rising tracheal collapse prevalence in small dog breeds, minimally invasive interventional veterinary medicine adoption, and expanding endoscopic airway intervention options at specialist respiratory centres.The first driving factor is rising tracheal collapse prevalence in small dog breeds, a progressive condition that becomes a leading cause of chronic respiratory distress and drives structural demand for nitinol airway stent intervention.The second driving factor is minimally invasive interventional veterinary medicine adoption, extending catheter-based and endoscopic device placement technique from human medicine into companion animal specialty care.The third driving factor is expanding endoscopic airway intervention options at specialist respiratory centres, as clinical evidence for both nitinol and silicone stent platforms continues to accumulate and inform veterinary treatment protocol development.These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a human-grade device platform's clinical validation in veterinary applications widens its addressable veterinary procedure volume every time a specialist respiratory or interventional centre adopts the adapted human technology, converting a device originally developed and commercially proven for human patients into a veterinary revenue stream without requiring the manufacturer to develop an entirely new veterinary-specific product from scratch.Once a human-grade device platform accumulates sufficient veterinary clinical evidence supporting its safety and efficacy in animal patients, every specialist veterinary interventional centre that adopts the technology becomes a procedure volume source for a device the manufacturer already commercialises at scale for human medicine, so veterinary revenue compounds on top of an already-established human device platform rather than requiring dedicated veterinary product development investment.As a result, demand and revenue share are concentrating around device platforms with the deepest accumulated veterinary clinical evidence supporting off-label or adapted use, that hold the broadest combined human commercial scale and veterinary applicability, and the forecast tilts toward these evidence-validated adapted platforms rather than dedicated veterinary-only stent development requiring independent commercial justification.For instance, published veterinary clinical evidence continues to document the efficacy of Dumon silicone stents, originally developed by Boston Medical Products for human airway stenosis, in treating dogs with grade IV tracheal collapse unresponsive to medical management, extending an established human respiratory device platform into a genuine veterinary treatment option through accumulated clinical evidence rather than dedicated veterinary product development.These are some of the key factors driving revenue growth of the market.

Because self-expanding nitinol airway stents can experience mechanical fracture or migration over extended placement duration in actively growing or highly mobile canine patients, this creates a genuine long-term complication risk that requires ongoing clinical monitoring and occasionally re-intervention.

Limited specialist interventional veterinary training availability is a second constraint, as fluoroscopically-guided stent placement requires specialised procedural training concentrated at a limited number of academic and specialty referral centres rather than broadly available across general veterinary practice.

High procedure and device cost relative to euthanasia as an alternative outcome is a third constraint, as the combined cost of stent placement, imaging, and specialist referral can approach or exceed what many pet owners are willing or able to spend, particularly without pet insurance coverage for the underlying condition.

These factors substantially limit veterinary stents market growth over the forecast period.

The clearest driver of demand is the persistent and progressive nature of tracheal collapse in predisposed small dog breeds, sustaining structural demand for airway stent intervention as a treatment of last resort when medical management fails. A veterinary stent manufacturer only captures durable airway stent revenue if the underlying disease prevalence and treatment protocol continue supporting stent placement as the clinical standard, and self-expanding nitinol mesh stents remain the treatment of choice for grade IV tracheal collapse when respiratory distress becomes severe and medical management alone is insufficient. Intraluminal tracheal stenting technique, placing an inert metal stent within the trachea under fluoroscopic guidance using an oropharyngeal approach, has been refined over more than 15 years of clinical use, with the current generation of self-expanding, flexible, woven nitinol stents representing the established standard of care. Tracheal stents are typically oversized by 2 to 3 millimetres compared to the expanded trachea diameter specifically to minimise future foreshortening and migration risk, reflecting continued refinement of placement protocol even as the underlying stent technology itself has remained relatively stable. The effect on the market is that airway stent demand continues tracking closely with underlying tracheal collapse disease prevalence in predisposed small dog breeds, sustaining the product category's position as the largest single veterinary stent segment. These are some of the key factors driving revenue growth of the market.

The second driver is the expansion of veterinary airway intervention options as clinical evidence accumulates supporting additional device platforms beyond the established nitinol stent standard. A silicone stent platform only becomes a genuine veterinary treatment option if published clinical evidence demonstrates its safety and efficacy specifically in animal patients, and documented case series evaluating Dumon silicone stents in dogs with grade IV tracheal collapse unresponsive to medical management found the platform an effective treatment alternative, with survival times after stent placement ranging from 97 to 1,310 days across the documented case cohort. Complications documented across silicone stent placement cases, including granulation tissue growth and stent migration, occurred in the majority of cases, reflecting that expanding treatment options does not eliminate the underlying complication risk inherent to airway stent placement regardless of material platform. Minimally invasive interventional veterinary medicine adoption more broadly continues extending catheter-based and endoscopic device placement technique from human medicine into companion animal specialty care, with imaging and minimally invasive technique improvements supporting faster stent placement confirmation and improved animal recovery times. The effect on the market is that veterinary interventional specialists are gaining a broader range of clinically evidenced device platform options for airway intervention, even as each platform, whether nitinol or silicone, continues carrying its own distinct complication profile requiring careful case-by-case clinical judgment. These are some of the key factors driving revenue growth of the market.

“Documented case series evaluating Dumon silicone stents, originally developed for human airway stenosis, in dogs with grade IV tracheal collapse found survival times after placement ranging from 97 to 1,310 days, extending an established human respiratory device platform into a genuine veterinary treatment option through accumulated clinical evidence.”

However, the veterinary stents market faces severe adoption constraints from stent fracture and migration complication risk, limited specialist interventional veterinary training availability, and high procedure cost relative to alternative outcomes.

Because self-expanding nitinol airway stents can experience mechanical fracture or migration over extended placement duration, with documented case series identifying stent fractures in a meaningful minority of treated dogs, some requiring re-stenting after several months, this creates a genuine long-term complication risk that requires ongoing clinical monitoring and occasionally repeat intervention.

Limited specialist interventional veterinary training availability compounds this, as fluoroscopically-guided stent placement requires specialised procedural training concentrated at a limited number of academic and specialty referral centres rather than broadly available across general veterinary practice, restricting patient access to specialist centres regardless of underlying disease prevalence.

High procedure and device cost relative to alternative outcomes is the third constraint, as the combined cost of stent placement, imaging, and specialist referral can approach or exceed what many pet owners are willing or able to spend, particularly without pet insurance coverage for the underlying condition, so device availability alone does not guarantee treatment access for every diagnosed patient.

These factors substantially limit veterinary stents market growth over the forecast period.

Based on product type, the global veterinary stents market is segmented into airway, urethral, vascular, and other stents. Airway stents hold the largest revenue share, because tracheal collapse in predisposed small dog breeds represents the single largest and most clinically established veterinary stent indication. Urethral stents are expected to register the fastest revenue growth rate over the forecast period, driven by expanding minimally invasive treatment options for urinary tract obstruction at manufacturers including Infiniti Medical and TaeWoong Medical.

Based on material, the global veterinary stents market is segmented into self-expanding nitinol, silicone, and biodegradable polymer stents. Self-expanding nitinol stents hold the largest material revenue share, reflecting their established position as the standard-of-care material for veterinary tracheal collapse intervention. Silicone stents are expected to register the fastest revenue growth rate, driven by accumulating clinical evidence supporting Dumon-type silicone platforms as an alternative treatment option for cases where nitinol stent complications have occurred.

Based on regional analysis, the veterinary stents market in North America accounted for largest revenue share in 2025. The United States leads because it hosts the headquarters of Infiniti Medical and Dextronix, and because the concentration of academic veterinary teaching hospitals and specialty interventional referral centres sustains the highest per-capita veterinary stent placement rate globally. The AVMA's published clinical research evaluating silicone stent platforms in dogs with tracheal collapse reflects the concentration of veterinary interventional clinical research infrastructure at US academic veterinary institutions specifically. The concentration of leading veterinary stent manufacturers and specialist interventional training programmes in the United States also means new stent placement technique and clinical evidence are typically established domestically before being extended to other regions.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, the United Kingdom, France, and the Netherlands represent the four largest national markets, with established veterinary specialty referral centre infrastructure supporting stent placement procedures. European veterinary interventional specialty training continues developing alongside academic veterinary institutions, but the concentration of specialist training capacity relative to the United States creates more measured procedure volume growth. The result is steady rather than rapid growth, shaped more by specialist training capacity than by underlying tracheal collapse disease prevalence.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period, driven by South Korea's TaeWoong Medical manufacturing base and Japan's expanding companion animal veterinary specialty infrastructure. South Korea's established position as a stent manufacturing base and Japan's growing veterinary specialty referral centre network are the region's two largest growth contributors, though specialist interventional training remains concentrated at tier-1 academic institutions. This leaves more room for growth than in the more mature North American and European veterinary stents markets, where manufacturer-institution relationships are already largely established.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national markets, with veterinary stent access concentrated at specialty referral centres in São Paulo and Mexico City. Iran-US sanctions continue to disrupt freight and import costs for the specialised nitinol wire, silicone, and biodegradable polymer materials that Latin American veterinary stent manufacturers and distributors depend on, with cargo rerouting around the Strait of Hormuz corridor raising landed material costs and slowing stent distribution beyond the region's main specialty referral centres through 2026.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary GCC commercial markets, with the Saudi Vision 2030 healthcare investment programme extending to veterinary specialty infrastructure development. The UAE is the most established market on the continent for advanced veterinary interventional procedure capability, while the Gulf states more broadly are still building specialist veterinary referral infrastructure largely from scratch.